NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

BioCryst Pharmaceuticals logo
$7.22 -0.10 (-1.30%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$7.24 +0.01 (+0.19%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

Advanced

Key Stats

Today's Range
$7.15
▼
$7.39
50-Day Range
$7.23
▼
$8.78
52-Week Range
$6.23
▼
$11.22
Volume
3.85 million shs
Average Volume
5.11 million shs
Market Capitalization
$1.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.38
Consensus Rating
Moderate Buy

Company Overview

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments.

Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.

BioCryst serves patients in the United States and other markets through its commercial operations and regional partners. Charlie Gayer is the company’s president and chief executive officer.

AI Generated. May Contain Errors.

BioCryst Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

BCRX MarketRank™: 
2.39789473684 of 5 stars

BioCryst Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 505th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    BioCryst Pharmaceuticals has a consensus price target of $20.38, representing about 182.0% upside from its current price of $7.23.

  • Amount of Analyst Coverage

    BioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioCryst Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($2.28) to $0.70 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCryst Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCryst Pharmaceuticals is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    11.17% of the float of BioCryst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 5.09.
  • Change versus previous month

    Short interest in BioCryst Pharmaceuticals has recently increased by 3.91%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    BioCryst Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    BioCryst Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    BioCryst Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BioCryst Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.80% of the stock of BioCryst Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioCryst Pharmaceuticals' insider trading history.
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCRX Stock News Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
BioCryst Earnings Call Highlights ORLADEYO Growth
See More Headlines

BCRX Stock Analysis - Frequently Asked Questions

BioCryst Pharmaceuticals' stock was trading at $7.80 at the beginning of the year. Since then, BCRX shares have decreased by 7.4% and is now trading at $7.2250.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The company's quarterly revenue was up 13.1% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of BioCryst Pharmaceuticals include State Street Corp (4.78%), Aberdeen Group plc (2.53%), Goldman Sachs Group Inc. (1.65%) and GW&K Investment Management LLC (1.31%). Insiders that own company stock include Alane P Barnes, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders and Steve Aselage.
View institutional ownership trends
.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Marvell Technology (MRVL), Micron Technology (MU) and Novavax (NVAX).

Company Calendar

Last Earnings
11/04/2026
Today
11/21/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCRX
CIK
882796
Employees
435
Year Founded
1986

Price Target and Rating

High Price Target
$32.00
Low Price Target
$11.00
Potential Upside/Downside
+182.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
10.32
P/E Growth
N/A
Net Income
$263.86 million
Net Margins
-37.40%
Pretax Margin
-36.89%
Return on Equity
-92.91%
Return on Assets
66.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.71
Quick Ratio
2.64

Sales & Book Value

Annual Sales
$874.84 million
Price / Sales
2.12
Cash Flow
$1.24 per share
Price / Cash Flow
5.83
Book Value
($1.54) per share
Price / Book
-4.69

Miscellaneous

Outstanding Shares
257,300,000
Free Float
247,522,000
Market Cap
$1.86 billion
Optionable
Optionable
Beta
0.55

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:BCRX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners